- Updated preliminary results from a Phase 1 clinical trial evaluating miRagen Therapeutics' (NASDAQ:MGEN) lead candidate MRG-106 in patients with the mycosis fungoides form of cutaneous T-cell lymphoma (CTCL) showed a treatment effect. The data are being presented today at the T-cell Lymphoma Forum in La Jolla, CA.
- 90% (n=26/29) of evaluable patients showed improvement in a metric called mSWAT score which measures the severity of skin disease over the entire body. Improvements in mSWAT scores were observed as early as 17 days after the first dose of MRG-106. The best improvements were seen after one or more months of dosing.
- Eight patients achieved at least a 50% improvement (reduction) in mSWAT score. All received long-term dosing and maintained their responses for more than four months. 80% (n=4/5) of patients who received 300 mg IV infusions achieved at least a 50% improvement in mSWAT score so this is the probable dose for a Phase 2 study, expected to launch in H2.
- MRG-106 is an inhibitor of microRNA-155. In CTCL, as well as certain other blood cancers, microRNA-155 is present at abnormally high levels and may play a role in the proliferation of blood and lymph cells.
- Previously: miRagen Therapeutics presents new clinical data from MRG-106 on mycosis fungoides; shares ahead 11% premarket (Oct. 13, 2017)
- Now read: Miragen Therapeutics May Provide Long-Term Alpha Within The RNA Space
Original article